Are the Cardiorenal Benefits of SGLT2 Inhibitors Due to Inhibition of the Sympathetic Nervous System? - PubMed (original) (raw)

Editorial

Are the Cardiorenal Benefits of SGLT2 Inhibitors Due to Inhibition of the Sympathetic Nervous System?

Subodh Verma. JACC Basic Transl Sci. 2020.

No abstract available

Keywords: SGLT2 inhibitors; cardiorenal benefits; mechanisms; sympathetic nervous system.

PubMed Disclaimer

Figures

Graphical abstract

Figure 1

SGLT2 Inhibition and SNS Regulation Sodium glucose cotransporter 2 (SGLT2) inhibitors, secondary to reducing renal stress, may reduce afferent renal sympathetic nervous system (SNS) activation. A reduction in central SNS activation may serve as an important mechanism of heart failure protection and reduce renal SGLT2 expression.

Comment on

• SGLT2 Inhibitor-Induced Sympathoinhibition: A Novel Mechanism for Cardiorenal Protection.
  Herat LY, Magno AL, Rudnicka C, Hricova J, Carnagarin R, Ward NC, Arcambal A, Kiuchi MG, Head GA, Schlaich MP, Matthews VB. Herat LY, et al. JACC Basic Transl Sci. 2020 Jan 29;5(2):169-179. doi: 10.1016/j.jacbts.2019.11.007. eCollection 2020 Feb. JACC Basic Transl Sci. 2020. PMID: 32140623 Free PMC article.

Similar articles

• A Systematic Review of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Sympathetic Nervous System Inhibition: An Underrated Mechanism of Cardiorenal Protection.
  Raza S, Osasan S, Sethia S, Batool T, Bambhroliya Z, Sandrugu J, Lowe M, Okunlola O, Hamid P. Raza S, et al. Cureus. 2022 Jun 25;14(6):e26313. doi: 10.7759/cureus.26313. eCollection 2022 Jun. Cureus. 2022. PMID: 35898359 Free PMC article. Review.
• SGLT2 Inhibitor-Induced Sympathoinhibition: A Novel Mechanism for Cardiorenal Protection.
  Herat LY, Magno AL, Rudnicka C, Hricova J, Carnagarin R, Ward NC, Arcambal A, Kiuchi MG, Head GA, Schlaich MP, Matthews VB. Herat LY, et al. JACC Basic Transl Sci. 2020 Jan 29;5(2):169-179. doi: 10.1016/j.jacbts.2019.11.007. eCollection 2020 Feb. JACC Basic Transl Sci. 2020. PMID: 32140623 Free PMC article.
• An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors.
  Salvatore T, Galiero R, Caturano A, Rinaldi L, Di Martino A, Albanese G, Di Salvo J, Epifani R, Marfella R, Docimo G, Lettieri M, Sardu C, Sasso FC. Salvatore T, et al. Int J Mol Sci. 2022 Mar 26;23(7):3651. doi: 10.3390/ijms23073651. Int J Mol Sci. 2022. PMID: 35409011 Free PMC article. Review.
• SGLT2 inhibitors for the composite of cardiorenal outcome in patients with chronic kidney disease: A systematic review and meta-analysis of randomized controlled trials.
  Chen HB, Yang YL, Yu TH, Li YH. Chen HB, et al. Eur J Pharmacol. 2022 Dec 5;936:175354. doi: 10.1016/j.ejphar.2022.175354. Epub 2022 Oct 25. Eur J Pharmacol. 2022. PMID: 36306924
• Comparable Cardiorenal Benefits of SGLT2 Inhibitors and GLP-1RAs in Asian and White Populations: An Updated Meta-analysis of Results From Randomized Outcome Trials.
  Tang H, Kimmel SE, Smith SM, Cusi K, Shi W, Gurka M, Winterstein AG, Guo J. Tang H, et al. Diabetes Care. 2022 Apr 1;45(4):1007-1012. doi: 10.2337/dc21-1722. Diabetes Care. 2022. PMID: 35349656 Review.

Cited by

• Dapagliflozin Enhances Arterial and Venous Compliance During Exercise in Heart Failure With Preserved Ejection Fraction: Insights From the CAMEO-DAPA Trial.
  Tada A, Burkhoff D, Naser JA, Harada T, Pourmussa B, Reddy YNV, Jensen MD, Carter RE, Demmer RT, Testani JM, Chirinos JA, Borlaug BA. Tada A, et al. Circulation. 2024 Sep 24;150(13):997-1009. doi: 10.1161/CIRCULATIONAHA.124.068788. Epub 2024 Aug 5. Circulation. 2024. PMID: 39101201 Clinical Trial.
• Potential Underlying Mechanisms Explaining the Cardiorenal Benefits of Sodium-Glucose Cotransporter 2 Inhibitors.
  Verma S, Mudaliar S, Greasley PJ. Verma S, et al. Adv Ther. 2024 Jan;41(1):92-112. doi: 10.1007/s12325-023-02652-5. Epub 2023 Nov 9. Adv Ther. 2024. PMID: 37943443 Free PMC article. Review.
• In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: Insights from the SGLT2-I AMI PROTECT study.
  Cesaro A, Gragnano F, Paolisso P, Bergamaschi L, Gallinoro E, Sardu C, Mileva N, Foà A, Armillotta M, Sansonetti A, Amicone S, Impellizzeri A, Esposito G, Morici N, Oreglia JA, Casella G, Mauro C, Vassilev D, Galie N, Santulli G, Pizzi C, Barbato E, Calabrò P, Marfella R. Cesaro A, et al. Front Cardiovasc Med. 2022 Sep 27;9:1012220. doi: 10.3389/fcvm.2022.1012220. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 36237914 Free PMC article.
• Renoprotective Effects of SGLT2 Inhibitors.
  Vallon V. Vallon V. Heart Fail Clin. 2022 Oct;18(4):539-549. doi: 10.1016/j.hfc.2022.03.005. Heart Fail Clin. 2022. PMID: 36216484 Free PMC article. Review.
• Sodium-Glucose Cotransporter 2 Inhibitors and Cardiac Remodeling.
  Salah HM, Verma S, Santos-Gallego CG, Bhatt AS, Vaduganathan M, Khan MS, Lopes RD, Al'Aref SJ, McGuire DK, Fudim M. Salah HM, et al. J Cardiovasc Transl Res. 2022 Oct;15(5):944-956. doi: 10.1007/s12265-022-10220-5. Epub 2022 Mar 15. J Cardiovasc Transl Res. 2022. PMID: 35290593 Review.

References

1. 1. Verma S., McMurray J.J.V. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018;61:2108–2117. - PubMed
2. 1. Verma S., Mazer C.D., Yan A.T. Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART CardioLink-6 randomized clinical trial. Circulation. 2019;140:1693–1702. - PubMed
3. 1. Verma S., Rawat S., Ho K.L. Empagliflozin increases cardiac energy production in diabetes: novel translational insights into the heart failure benefits of SGLT2 inhibitors. J Am Coll Cardiol Basic Trans Sci. 2018;3:575–587. - PMC - PubMed
4. 1. Mazer C.D., Hare G.M.T., Connelly P.W. Effect of empagliflozin on erythropoietin levels, iron stores and red blood cell morphology in patients with type 2 diabetes and coronary artery disease. Circulation. 2019 Nov 11 [E-pub ahead of print] - PubMed
5. 1. Herat L.Y., Magno A.L., Rudnicka C. SGLT2 inhibitor–induced sympathoinhibition: a novel mechanism for cardiorenal protection. J Am Coll Cardiol Basic Trans Science. 2020;5:169–179. - PMC - PubMed

Publication types

LinkOut - more resources

• Full Text Sources

  • Elsevier Science
  • Europe PubMed Central
  • PubMed Central